Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Gilead Sciences (NQ: GILD )

66.69 +0.10 (+0.15%)
Streaming Delayed Price Updated: 4:00 PM EDT, Jul 5, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Gilead Sciences

< Previous 1 2
...
25 26 27 28 29 30 31 32 Next >
Dividend Initiators: A Fertile Ground For Research
Only a company with a certain type of business can afford to grow dividends over a full business cycle. 
Via Talk Markets
Gilead Files US Application For Bulevirtide In Severe Form Of Viral Hepatitis
Gilead Sciences Inc (NASDAQ: GILD) has submitted a marketing application to FDA for bulevirtide for injection (2 mg) for chronic hepatitis delta virus (HDV)... 
Via Benzinga
Exposures Product Safety
Arcus Stock Rockets To Record As Gilead Unexpectedly Opts Into Cancer Drugs
Gilead opted into three programs from a small biotech company, sending shares flying. 
Via Investor's Business Daily
Why Are Arcus Biosciences Shares Trading Higher Today?
Gilead Sciences Inc (NASDAQ: GILD) has exercised its options to three programs in Arcus Biosciences Inc (NYSE: RCUS) portfolio, including both anti-TIGIT... 
Via Benzinga
Why Arcus Biosciences Stock Is On Fire Today
Gilead Sciences has decided to exercise its options for three of the biotech's oncology programs. 
Via The Motley Fool
This Cheap Stock Is Paying An Unusually High Yield
Gilead has increased their dividend for seven consecutive years. The three-year dividend growth rate of 9.4% shows the level of growth they’re capable of delivering. 
Via Talk Markets
Gilead Sciences (GILD) Q3 Earnings and Revenues Surpass Estimates
Gilead Sciences came out with quarterly earnings of $2.65 per share. 
Via Talk Markets
GILD: Is This Biotech’s 4.2% Yield Healthy?
Gilead’s free cash flow hit a recent peak of $19.5 billion in 2015 before falling each of the next two years, settling around $7.5 billion in 2018. 
Via Talk Markets
2 High-Yield Dividend Stocks That Can Safeguard Your Portfolio Against a Market Crash
AbbVie and Gilead Sciences are two top high-yield stocks that could save your portfolio in the event of a marketwide downturn. 
Via The Motley Fool
Topics Economy
Exposures Interest Rates
On Target: This Company Says It Delivers Drugs Exactly How You Need Them
Photo by Anna Shvets from Pexels The following post was written and/or published as a collaboration between Benzinga’s in-house sponsored content team and a financial... 
Via Benzinga
Large Cap Biopharmaceuticals Metrics and Review: JNJ Splits Up
Today JNJ announced a split of the Company separating its legacy consumer products from higher growth growing biopharmaceutical and medtech products. 
Via Talk Markets
The Daily Biotech Pulse: Eisai-Gilead Tout Positive Phase 2 Data For New Alzheimer's Treatment, Compugen Spikes On Bristol-Myers Investment, Vaxxinity Debuts
Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus Merck Commences Late-Stage Study Of Heart Failure Treatment Merck &... 
Via Benzinga
Top 5 Stocks To Buy In November 2021
High-quality dividend growth stocks are some of the very best stocks in the whole world. They represent equity in world-class businesses that pay reliable, rising dividends. 
Via Talk Markets
How Are Biotech ETFs Reacting To These Q3 Earnings Releases?
There's no denying that the pandemic has opened up investment opportunities in the biotech sector by triggering a race to introduce vaccines. Let’s take a look at big biotech earnings releases to see... 
Via Talk Markets
Best and Worst Performers Since the COVID Crash Low
The major indices have consistently been hitting new record highs over the past few days with the S&P 500 having now more than doubled off the COVID Crash low on March 23, 2020. 
Via Talk Markets
Topics Stocks
Exposures US Equities
Will Pfizer Outgun Merck With Oral COVID-19 Pill?
Merck, Inc. (NYSE: MRK) is locking horns with peer Pfizer, Inc. (NYSE: PFE) in what could be termed as the battle supremacy in the COVID-19 treatment market. The stakes are high,... 
Via Benzinga
Exposures COVID-19
Todos Medical Says It Wants to Outfox COVID-19 & Cancer Along With Rivals Pfizer & Merck With New Theranostic Approach
Photo by Artem Podrez from Pexels The following post was written and/or published as a collaboration between Benzinga’s in-house sponsored content team and a financial... 
Via Benzinga
Exposures COVID-19
A Deep Dive Into COVID Oral Treatments — What Does the Atea Failure Mean for Oral Antivirals?
Photo by Danilo Alvesd on Unsplash The following post was written and/or published as a collaboration between Benzinga’s in-house sponsored content team and a financial... 
Via Benzinga
NRx Pharma Stock Nosedives As FDA Strikes Off Its COVID-19 Drug Hopeful
The FDA has declined the emergency use authorization (EUA) for NRx Pharmaceuticals' (NASDAQ: NRXP) Zyesami (aviptadil). The Company is developing... 
Via Benzinga
Exposures COVID-19 Product Safety
Attention Biotech Investors: Mark Your Calendar For November PDUFA Dates
The loaded Prescription Drug User Fee Act (PDUFA) calendar for October produced mixed outcomes. PDUFA dates are key binary events for biotech stocks that can move the needle in a... 
Via Benzinga
Healthcare Stocks Subject to Government Policy
The market this morning isn’t moving much, but today’s tepid start is coming on the heels of yesterday’s record closes on the Dow, the S&P 500, and the... 
Via Benzinga
Topics Stocks
Exposures US Equities
5 M&A Stocks to Watch as Goldman Calls for a Big Jump in Deals
Goldman Sachs predicts the Democrats' new tax plan could yield positive results for M&A-focused companies. Here are the M&A stocks to watch. 
Via InvestorPlace
Gilead Sciences (GILD) Q3 2021 Earnings Call Transcript
GILD earnings call for the period ending September 30, 2021. 
Via The Motley Fool
Topics Earnings
Exposures Financial
The Daily Biotech Pulse: Gilead-Merck Collaborate For Breast Cancer Study, Decision Day For ANI Pharma, Pfizer Gets Canadian Regulatory Nod, 3 IPOs
Here's a roundup of top developments in the biotech space over the last 24 hours. Stocks In Focus Gilead, Merck to Study Trodelvy-Keytruda Combo For Breast Cancer Gilead, Inc... 
Via Benzinga
The Week Ahead In Biotech (Oct. 31-Nov. 6): Earnings Pick Up Pace, Eton Awaits Seizure Drug Approval, Kidney Conference, More IPOs In The Pipeline
Biotech stocks rose a third week running in the week ending Oct. 29 amid positive reaction to earnings. Big pharma earnings were mostly better than expected. Merck & Co, Inc... 
Via Benzinga
Gilead Trims Non-COVID Product Sales Outlook, Though Q3 Earnings Beat Street Estimates
Gilead Sciences Inc (NASDAQ: GILD) posted higher-than-expected Q3 earnings on strong demand for its COVID-19 antiviral treatment. Adjusted EPS increased 26% Y/Y to... 
Via Benzinga
Topics Earnings
Exposures COVID-19 Financial
Recap: Gilead Sciences Q3 Earnings
Gilead Sciences (NASDAQ:GILD) reported its Q3 earnings results on Thursday, October 28, 2021 at 04:01 PM. Here's what investors need to know about the announcement. Earnings... 
Via Benzinga
Gilead Crushes Quarterly Forecasts and Raises Outlook For 2021; But Shares Dip
Gilead beat Wall Street's quarterly forecasts and raised its outlook for 2021. 
Via Investor's Business Daily
Pfizer Conceding Race in Hospitalized Covid Because of Todos Medical's Triple MOA Antiviral
Photo by Christina Victoria Craft on Unsplash The following post was written and/or published as a collaboration between Benzinga’s in-house sponsored content team and a... 
Via Benzinga
Gilead Sciences Earnings Preview
Gilead Sciences (NASDAQ:GILD) is set to give its latest quarterly earnings report on Thursday, 2021-10-28. Here's what investors need to know before the announcement. Analysts... 
Via Benzinga
< Previous 1 2
...
25 26 27 28 29 30 31 32 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.